Skip to main content

ASCO’s and FDA’s approach to biosimilars in oncology

By 19 Aprile 2019Maggio 12th, 2021No Comments
Dai congressiSpeciali

We talked about ASCO’s and FDA’s approach to biosimilars in oncology with R. Donald Harvey, Department of Hematology and Medical Oncology, Department of Pharmacology and Chemical Biology of Emory University, Atlanta, met during ISPE’S 2019 Mid-Year Meeting, in Rome.